Acid Sphingomyelinase Deficiency
📧 Sign up to get email alerts when something new happens for Acid Sphingomyelinase Deficiency.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-01-19EMA Authorised: Xenpozyme (olipudase alfa) — Sanofi B.V.
The EMA authorised Xenpozyme (olipudase alfa) for the treatment of Acid sphingomyelinase deficiency (ASMD) types A/B or type B. It has been …
-
FDA approval · 2024-12-20FDA Approved: XENPOZYME — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for XENPOZYME (olipudase alfa-RPCP) from Genzyme Corporation.
-
FDA approval · 2023-12-05FDA Approved: XENPOZYME — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for XENPOZYME (olipudase alfa-rpcp) from Genzyme Corporation. This supplemental approval concerns th…
-
FDA approval · 2022-08-31FDA Approved: XENPOZYME — Original Application (Genzyme Corporation)
FDA approved XENPOZYME (olipudase alfa-rpcp) from Genzyme in an original application to treat acid sphingomyelinase deficiency (ASMD), inclu…